Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 972
countries
28
conditions
2 103

9 trials match your criteria

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib

Prolymphocytic leukaemia+2

Recruiting

Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab

Transitional cell carcinoma

Not recruiting

Study on the Effectiveness and Safety of Erdafitinib, Midazolam, and Metformin in Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib

Neoplasm

Not recruiting

Study of erdafitinib treatment for adults and adolescents with advanced solid tumors having FGFR gene changes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Erdafitinib

Transitional cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Erdafitinib Alone or with Cetrelimab and Chemotherapy for Patients with Metastatic or Advanced Urothelial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Transitional cell carcinoma

Not recruiting

Study Comparing Erdafitinib with Vinflunine, Docetaxel, or Pembrolizumab for Patients with Advanced Urothelial Cancer and FGFR Gene Changes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Bladder transitional cell carcinoma

Not recruiting

Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.